X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (6) 6
adult (4) 4
aged (4) 4
female (4) 4
humans (4) 4
middle aged (4) 4
oncology (4) 4
antineoplastic agents - adverse effects (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
antineoplastic combined chemotherapy protocols - pharmacokinetics (3) 3
care and treatment (3) 3
dosage and administration (3) 3
hematology, oncology and palliative medicine (3) 3
male (3) 3
medicine & public health (3) 3
neoplasms - drug therapy (3) 3
pharmacokinetics (3) 3
pharmacology & pharmacy (3) 3
research (3) 3
studies (3) 3
tumors (3) 3
afatinib (2) 2
aged, 80 and over (2) 2
analysis (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents - pharmacokinetics (2) 2
antineoplastic agents - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - blood (2) 2
chemotherapy (2) 2
clinical trials (2) 2
complications and side effects (2) 2
deoxycytidine - analogs & derivatives (2) 2
drug administration schedule (2) 2
hematology (2) 2
maximum tolerated dose (2) 2
medical research (2) 2
metastasis (2) 2
neoplasms - blood (2) 2
pharmacology/toxicology (2) 2
phase 1 (2) 2
protein kinase inhibitors - adverse effects (2) 2
protein kinase inhibitors - therapeutic use (2) 2
quinazolines - administration & dosage (2) 2
quinazolines - adverse effects (2) 2
sickle cell disease (2) 2
abstinence (1) 1
added value (1) 1
advanced hepatocellular-carcinoma (1) 1
age (1) 1
alcoholism (1) 1
antigens (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic agents - blood (1) 1
antineoplastic agents - pharmacology (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
area under curve (1) 1
aurora kinase inhibitor (1) 1
barasertib azd1152 (1) 1
bay 43-9006 (1) 1
benzenesulfonates - administration & dosage (1) 1
bibw 2992 (1) 1
bibw-2992 (1) 1
biology and life sciences (1) 1
biomarkers, tumor - metabolism (1) 1
blood (1) 1
blood transfusion (1) 1
breast cancer (1) 1
breast neoplasms - drug therapy (1) 1
breast neoplasms - metabolism (1) 1
breast neoplasms - mortality (1) 1
breast neoplasms - pathology (1) 1
breast-cancer (1) 1
cancer (1) 1
cancer research (1) 1
cancer therapies (1) 1
capecitabine (1) 1
carboplatin (1) 1
cardiac patients (1) 1
cd8 antigen (1) 1
cell activation (1) 1
cell lung-cancer (1) 1
cetuximab (1) 1
cisplatin (1) 1
clinical trial (1) 1
cohort studies (1) 1
colonic neoplasms - drug therapy (1) 1
colonic neoplasms - metabolism (1) 1
combination (1) 1
complications (1) 1
cue reactivity (1) 1
cytokines (1) 1
demography (1) 1
deoxycytidine - administration & dosage (1) 1
diagnosis (1) 1
diarrhea - chemically induced (1) 1
dose-response relationship (1) 1
dose-response relationship, drug (1) 1
drug therapy (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 4924 - 4924
Abstract Introduction: Previous studies reported that patients with sickle cell disease (SCD) present with alterations of several factors involved in the... 
Journal Article
Value in Health, ISSN 1098-3015, 11/2015, Volume 18, Issue 7, pp. A485 - A485
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 8/2012, Volume 134, Issue 3, pp. 1149 - 1159
Journal Article
Value in Health, ISSN 1098-3015, 2015, Volume 18, Issue 7, pp. A485 - A485
Journal Article
Investigational New Drugs, ISSN 0167-6997, 6/2013, Volume 31, Issue 3, pp. 734 - 741
Background A phase I study to assess the maximum tolerated dose (MTD) of a short course of afatinib in combination with docetaxel for the treatment of solid... 
BIBW 2992 | Phase I | Medicine & Public Health | Afatinib | Tyrosine kinase inhibitor | Oncology | Pharmacology/Toxicology | Pharmacokinetics | Epidermal growth factor receptor | GEFITINIB | CARBOPLATIN | KINASE INHIBITOR | BIBW-2992 | LINES | PACLITAXEL | CELL LUNG-CANCER | TRIAL | ONCOLOGY | PHARMACOLOGY & PHARMACY | ERLOTINIB | Skin Diseases - chemically induced | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Drug Administration Schedule | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Quinazolines - pharmacokinetics | Male | Antineoplastic Agents - administration & dosage | Neoplasms - drug therapy | Taxoids - pharmacokinetics | Taxoids - administration & dosage | Maximum Tolerated Dose | Neoplasms - blood | Antineoplastic Agents - adverse effects | Quinazolines - adverse effects | Adult | Female | Quinazolines - administration & dosage | Aged | Antineoplastic Agents - pharmacokinetics | Gastrointestinal Diseases - chemically induced | Taxoids - adverse effects | Antimitotic agents | Complications and side effects | Patient outcomes | Dosage and administration | Research | Drug therapy, Combination | Antineoplastic agents | Drug therapy | Tumors | Studies | Medical research | Prescription drugs | Chemotherapy | Statistical analysis | Research & development--R&D | Pharmacology | Cancer therapies | Index Medicus | Phase I Studies
Journal Article
Investigational New Drugs, ISSN 0167-6997, 2/2014, Volume 32, Issue 1, pp. 94 - 103
Introduction MSC1992371A is an aurora kinase inhibitor with potential antitumor activity. Methods This trial established the maximum tolerated dose (MTD) and... 
Phase l | Aurora kinase inhibitor | Medicine & Public Health | Mitosis | Targeted therapy | Oncology | Pharmacology/Toxicology | MSC1992371A | Neutropenia | BARASERTIB AZD1152 | PHARMACOKINETICS | EFFICACY | ONCOLOGY | SAFETY | PHARMACOLOGY & PHARMACY | Phase 1 | Demography | Antineoplastic Combined Chemotherapy Protocols - blood | Pyrimidines - blood | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Norbornanes - blood | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Young Adult | Neoplasms - blood | Antineoplastic Agents - adverse effects | Norbornanes - adverse effects | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacokinetics | Norbornanes - pharmacokinetics | Protein Kinase Inhibitors - pharmacokinetics | Drug Administration Schedule | Norbornanes - therapeutic use | Protein Kinase Inhibitors - blood | Neoplasms - drug therapy | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Antineoplastic Agents - blood | Pyrimidines - pharmacokinetics | Aged | Deoxycytidine - analogs & derivatives | Dose-response relationship (Biochemistry) | Care and treatment | Pharmacology, Experimental | Enzyme inhibitors | Dosage and administration | Research | Tumors | Studies | Clinical trials | Inhibitor drugs | Kinases | Pharmaceutical sciences | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2010, Volume 28, Issue 15_suppl, pp. 2561 - 2561
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2011, Volume 29, Issue 15_suppl, pp. 3019 - 3019
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2010, Volume 28, Issue 15_suppl, pp. 2504 - 2504
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 12/2011, Volume 51, Issue 12, pp. 1674 - 1684
Sorafenib (twice daily [bid]) plus capecitabine (2 weeks on schedule/1 week off schedule) safety and pharmacokinetics were investigated in patients with... 
phase 1 | sorafenib | Capecitabine | solid tumors | combination | ADVANCED HEPATOCELLULAR-CARCINOMA | RAF KINASE | RENAL-CELL CARCINOMA | MULTIKINASE INHIBITOR | BAY 43-9006 | INHIBITOR BAY-43-9006 | BREAST-CANCER | I TRIAL | PHARMACOLOGY & PHARMACY | RANDOMIZED DISCONTINUATION TRIAL | Neoplasms - metabolism | Niacinamide - analogs & derivatives | Antineoplastic Combined Chemotherapy Protocols - blood | Area Under Curve | Colonic Neoplasms - drug therapy | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Fatigue - chemically induced | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Hand-Foot Syndrome - etiology | Diarrhea - chemically induced | Colonic Neoplasms - metabolism | Fluorouracil - administration & dosage | Adult | Female | Pyridines - administration & dosage | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Aged | Deoxycytidine - analogs & derivatives | Physiological aspects | Complications and side effects | Dosage and administration | Research | Side effects | Metabolites | Toxicity | Fatigue | Skin | Pharmacokinetics | Tumors
Journal Article
Cancer Research, ISSN 0008-5472, 12/2009, Volume 69, Issue 24 Supplement, pp. 4097 - 4097
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2008, Volume 26, Issue 15_suppl, pp. 14534 - 14534
Journal Article
European Journal of Cancer Supplements, ISSN 1359-6349, 2010, Volume 8, Issue 7, pp. 137 - 137
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.